论文部分内容阅读
本文453例重肝中,急性重型40例(8.8％),亚急性重型413例(91.2％)。乙肝总感染率为78.4％,非甲非乙型为19.6％。肝中HDAg阳性检出率为4.8％(5/104例),其中上海、天津和沈阳地区分别为4.5％、11.5％及1.7％。 324例有肝性脑病。Ⅰ°—Ⅳ°肝性脑病者病死率分别为0％、15.2％、42.9％及83.8％。凝血酶原活动度>60％、30％～60％和<30％患者的病死率分别为0％、20.1％及57.8％。常见并发症为出血(53.2％)、继发性感染(33.8％)及肝肾综合征(15.0％)。对采用的六种新疗法疗效作了初步评价。
This article 453 cases of severe liver, 40 cases of acute severe cases (8.8%), subacute heavy 413 cases (91.2%). The total infection rate of hepatitis B was 78.4%, non-A non-B was 19.6%. The positive detection rate of HDAg in liver was 4.8% (5/104 cases), of which, Shanghai, Tianjin and Shenyang were 4.5%, 11.5% and 1.7% respectively. 324 cases of hepatic encephalopathy. The mortality rates of Ⅰ ° -Ⅳ ° hepatic encephalopathy were 0%, 15.2%, 42.9% and 83.8% respectively. Patients with prothrombin activity> 60%, 30% -60% and <30% had 0%, 20.1% and 57.8% mortality, respectively. Common complications were bleeding (53.2%), secondary infection (33.8%) and hepatorenal syndrome (15.0%). Preliminary evaluation of the efficacy of the six new therapies used.